sermorelin protocol: Frequently asked questions

Expect minimal to no GH response for that dose. Elevated blood glucose triggers insulin release, which activates hypothalamic somatostatin neurons that directly inhibit GH secretion for 90–120 minutes post-meal. The peptide reaches your pituitary normally, binds to GHRH receptors as expected, but the downstream signal is suppressed before GH release occurs. If this happens, don't re-dose. Wait until the next scheduled injection and maintain proper meal-to-injection spacing going forward.

Rotate injection sites across at least four distinct areas (left/right abdomen, left/right deltoid) and verify you're injecting into subcutaneous fat, not intramuscular or intradermal layers. Persistent redness lasting beyond 24 hours at a single site suggests either repeated trauma to the same location or an immune response to a reconstitution vehicle component. Switch to bacteriostatic water if you're using saline, ensure the lyophilized powder fully dissolves before drawing, and avoid injecting into areas with visible surface veins.

Reduce to 200 mcg immediately and assess response over 14 days before increasing. Doses calibrated for populations with age-related GH decline produce somatostatin rebound in younger subjects. Your pituitary releases inhibitory peptides to counteract what it perceives as excessive stimulation, blunting the pulse you're trying to create. The dose-response curve in your 20s plateaus around 300 mcg; anything above that threshold increases side effect risk (headache, transient hypoglycemia, flushing) without proportional IGF-1 elevation.

Discard it. Peptides are temperature-sensitive biologics. Even 8–12 hours at 20–25°C degrades bioactivity by an estimated 15–25%, and you can't reverse that loss by refrigerating afterward. The denatured protein structure no longer binds effectively to GHRH receptors, meaning subsequent doses from that vial deliver unpredictable (likely minimal) GH stimulation. This is why our team emphasises cold chain discipline as the single most important protocol variable outside dosing itself.

Shift injection timing to first thing upon waking in a true fasted state (12+ hours post-last meal). Morning sermorelin administration in your 30s is suboptimal compared to nocturnal timing because daytime GH pulse frequency is already reduced in this age bracket, but fasted morning dosing outperforms post-meal evening dosing every time. The alternative: consume a light, low-glycemic final meal by 7:00 PM even if you eat a second time later, then inject at 9:00 PM before the later meal. Though this introduces complexity most users find unsustainable.

Resume at your standard dose on the next scheduled night. Do not double-dose to compensate. Missing 48 hours does not reset pituitary responsiveness or negate prior cycle progress, but it does create a temporary gap in GH elevation that may manifest as slightly reduced recovery quality for 3–4 days. The mechanism: sermorelin amplifies endogenous pulses rather than replacing them, so skipping doses simply returns you to baseline secretion temporarily. Consistent dosing 5–6 nights per week matters more than occasional missed nights.

No. Sermorelin works by synchronising with your endogenous nocturnal GH surge. Doubling a dose doesn't create a 'catch-up' pulse; it oversaturates GHRH receptors and triggers compensatory somatostatin release. If you miss a single dose, resume your standard 200–300 mcg the following night at the usual pre-sleep window. Missing 2–3 consecutive doses may cause a temporary dip in subjective recovery markers, but baseline GH production returns to normal within 48 hours of discontinuation.

These are histamine-mediated vasodilatory effects caused by rapid GH release. They occur in approximately 15–20% of patients during the first 2–4 weeks and typically resolve with continued use as tolerance develops. Counsel the patient to premedicate with 25–50 mg diphenhydramine 30 minutes before injection if symptoms are bothersome—this does not reduce sermorelin's efficacy. If symptoms persist beyond 4 weeks or worsen, reduce the dose to 200 mcg and titrate more slowly.

Reduce injection volume by increasing peptide concentration. If the patient is injecting 0.5ml per dose, switch to a more concentrated preparation that delivers the same 300mcg dose in 0.2ml. Larger injection volumes (>0.3ml) increase subcutaneous tissue distension and local inflammatory response, which manifests as redness, swelling, or itching at the injection site. Rotating injection sites (abdomen, thighs, upper arms) also reduces cumulative irritation. If reactions persist despite volume reduction and site rotation, the patient may have sensitivity to the bacteriostatic water preservative (benzyl alcohol). Switch to sterile water for injection, though this shortens post-reconstitution stability to 7–10 days instead of 28 days.

This indicates either pituitary insufficiency, incorrect peptide preparation, or peptide degradation due to storage failure. Order a comprehensive pituitary hormone panel (TSH, free T4, cortisol, LH, FSH, prolactin) to rule out broader anterior pituitary dysfunction. Isolated GH deficiency is uncommon in adults without concomitant deficiencies in other pituitary axes. If other pituitary hormones are normal, the issue is likely preparation or storage. Ask the patient to photograph their storage setup and describe their reconstitution process in detail. If both are correct, the peptide source may be the problem. Compounded sermorelin quality varies significantly between 503B facilities.

First action: verify reconstitution accuracy, injection timing, and storage conditions before adjusting the dose. Ask the patient to describe their exact reconstitution process step-by-step. The most common cause of non-response is incorrect dilution math (patient drew the wrong volume) or daytime injection timing (sermorelin must be present during the nocturnal GH pulse to work). If reconstitution and timing are confirmed correct, increase the dose to 400–500mcg for another four weeks and order baseline IGF-1 labs. True non-responders are rare. Fewer than 5% of patients with intact pituitary function fail to respond to sermorelin at therapeutic doses.

Be direct: sermorelin is not FDA-approved for weight loss or body composition optimization in individuals with normal GH levels. While clinical studies show modest improvements in lean mass and visceral fat reduction in GH-deficient populations, these effects require documented deficiency to justify prescribing. Off-label use in wellness contexts exposes the prescriber to liability and the patient to unnecessary injection burden without evidence of benefit. Telehealth clinicians researching sermorelin for body composition protocols should redirect those inquiries toward evidence-based GLP-1 agonists like semaglutide or tirzepatide, which have FDA approval for weight management.

Order follow-up IGF-1 testing to confirm pharmacological response—sermorelin's efficacy depends on residual pituitary function, and some patients with partial GH deficiency show blunted IGF-1 elevation even with adequate dosing. If IGF-1 remains below the age-adjusted reference range after 6 weeks, increase the dose to 500 mcg and retest at 8 weeks. If IGF-1 still does not rise, consider pituitary imaging (MRI with contrast) to rule out structural lesions or primary pituitary failure—these patients require somatropin, not GHRH agonism.

You can discontinue immediately without tapering. Sermorelin doesn't suppress the hypothalamic-pituitary axis, so there's no withdrawal protocol. IGF-1 levels will return to baseline over 4–8 weeks after stopping, and subjective markers (sleep quality, recovery) will gradually revert to pre-protocol status. If you're stopping because you've achieved goal body composition, consider maintenance dosing (200–300mcg three nights per week) rather than full discontinuation.

Sermorelin doesn't have a cumulative suppressive effect, so missed doses don't create rebound issues the way stopping synthetic GH does. Resume your normal schedule without doubling up. Consistency matters for optimizing results. Five to seven nights per week produces better IGF-1 restoration than three to four nights. But occasional missed doses don't reset progress. The peptide's half-life is 10–20 minutes, meaning each injection produces an acute pulse; there's no 'loading' phase.

IGF-1 reference ranges are population averages, not individual optima. A 50-year-old man with an IGF-1 level of 140ng/mL is 'in range' but may have been at 200ng/mL at age 30. Sermorelin can restore levels toward the upper quartile of the age-adjusted range without exceeding physiological limits. Additionally, growth hormone has direct effects on sleep architecture, lipolysis, and collagen synthesis that aren't fully mediated by IGF-1. Meaning symptomatic improvement can occur even with modest IGF-1 changes.

Resume at your current dose. Do not double-dose to compensate. Missing three nights interrupts the GH pulse amplification but doesn't reset adaptation. IGF-1 half-life is approximately 12–15 hours, so levels decline gradually rather than collapsing immediately. The primary consequence is delayed progress toward your 12-week body composition target, not loss of prior gains. Consistency matters more than perfection. A protocol administered 6 nights per week for 12 weeks outperforms a protocol administered perfectly for 6 weeks then sporadically thereafter.

Escalate to 400–500mcg nightly before concluding the protocol is ineffective. Men over 45 frequently require higher doses due to age-related declines in somatotroph receptor density. The same mechanism that makes thyroid hormone replacement less effective at standard doses in older populations. If you've been injecting at 300mcg for 6 weeks with no subjective improvement in sleep quality or recovery, the dose is insufficient for your pituitary reserve capacity. Retest IGF-1 at 8–10 weeks after escalation to confirm biochemical response.

Escalate to 400mcg nightly and retest at week 6. Non-response at 300mcg in men 35-45 typically indicates either poor injection timing (administered too close to meals), incorrect reconstitution (peptide degraded during mixing), or genuinely low pituitary reserve requiring higher GHRH stimulation. If IGF-1 remains unchanged after six weeks at 400mcg, the issue is upstream. Either hypothalamic or pituitary pathology that sermorelin cannot overcome. At that point, consultation with an endocrinologist for pituitary MRI and formal GH stimulation testing is warranted.

Reduce dose by 100mcg immediately and retest IGF-1 within two weeks. Joint pain and carpal tunnel symptoms are early markers of supra-physiological IGF-1 elevation. Typically occurring when levels exceed 280 ng/mL. These symptoms resolve within 7–10 days of dose reduction in most cases. If symptoms persist despite IGF-1 returning to target range, discontinue the protocol and evaluate for underlying inflammatory or autoimmune conditions unmasked by elevated GH/IGF-1 signaling.